Results 291 to 300 of about 640,298 (391)

Perioperative utilization of JAK inhibitors in Perianal Fistulizing Crohn's disease

open access: yesJPGN Reports, EarlyView.
Abstract With the recent approval of small molecule drugs such as upadacitinib in adult inflammatory bowel disease (IBD), their utilization is becoming more common; however, there is limited data on perioperative risks or optimal timing of cessation and resumption to mitigate flares. Current recommendations suggest holding these medications for 14 days
Alexander Lyons   +2 more
wiley   +1 more source

Ruxolitinib and vedolizumab salvage therapy in the setting of cytomegalovirus colitis for a patient with newly diagnosed very early onset inflammatory bowel disease

open access: yesJPGN Reports, EarlyView.
Abstract Acute severe ulcerative colitis increases the risk for cytomegalovirus (CMV) infection, particularly with the use of immunocompromising medications. We report a case of a 4‐year‐old with newly diagnosed very early onset inflammatory bowel disease presenting with acute severe colitis refractory to both corticosteroids and infliximab, whose ...
Alison Laxer   +3 more
wiley   +1 more source

Muscular and serosal eosinophilic gastritis and enteritis with eosinophilic ascites successfully treated with dupilumab

open access: yesJPGN Reports, EarlyView.
Abstract Primary eosinophilic gastrointestinal disorders beyond the esophagus (EGIDs) are rare, predominantly Th2‐mediated inflammatory conditions, affecting various segments of the gastrointestinal tract. We report the case of a 12‐year‐old boy with recurrent abdominal pain, peripheral eosinophilia, and progressive gastritis, duodenitis, and enteritis
Almudena Sánchez‐Ramírez   +6 more
wiley   +1 more source

The smoking epidemic in England [PDF]

open access: yes, 2004
Moon, G., Twigg, Liz, Walker, S.
core  

Severe allergic reaction to ustekinumab reinitiation in a pediatric patient with Crohn's disease: A case report

open access: yesJPGN Reports, EarlyView.
Abstract Ustekinumab (UST) is a monoclonal antibody used in the management of moderate to severe inflammatory bowel disease. While generally well‐tolerated, serious adverse reactions, including hypersensitivity and anaphylaxis, have been documented, specifical following the initial intravenous (IV) dose.
Kennedy Sparling   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy